Targeting more precisely: Improving sensitivity to EGFR inhibitors in NSCLC

Arjan Gower; Edward B Garon

doi:10.1016/j.medj.2021.10.005

Targeting more precisely: Improving sensitivity to EGFR inhibitors in NSCLC

Med. 2021 Nov 12;2(11):1201-1202. doi: 10.1016/j.medj.2021.10.005.

Authors

Arjan Gower¹, Edward B Garon²

Affiliations

¹ Division of Hematology and Oncology, David Geffen School of Medicine, UCLA, Los Angeles, CA, USA.
² Division of Hematology and Oncology, David Geffen School of Medicine, UCLA, Los Angeles, CA, USA. Electronic address: egaron@mednet.ucla.edu.

PMID: 35590196
DOI: 10.1016/j.medj.2021.10.005

Abstract

The therapeutic landscape of epidermal growth factor receptor (EGFR)-mutation-positive non-small cell lung cancer (NSCLC) is continually evolving. A recent manuscript in Nature by Robichaux and colleagues¹ reports on a structure-based classification of EGFR mutations to help predict sensitivities to EGFR inhibitors in NSCLC that may ultimately improve patient outcomes.

Publication types

Research Support, Non-U.S. Gov't
Comment

MeSH terms

Carcinoma, Non-Small-Cell Lung* / drug therapy
ErbB Receptors / genetics
Humans
Lung Neoplasms* / drug therapy
Mutation
Protein Kinase Inhibitors / pharmacology

Substances

Protein Kinase Inhibitors
EGFR protein, human
ErbB Receptors